Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.53 |
| ▸ | DBF4 | Q9UBU7 | 7/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892373 | 0.87 | FAAH (0.52) | FAAHALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL5111369 | 0.85 | FAAH (0.56) | CDC7DBF4FAAHALDH1A1HPGD | |
| SCHEMBL31301564 | 0.84 | TARBP2 (0.53) | ALDH1A1HPGDHSD17B10GAAKDM4E | |
| SCHEMBL6819068 | 0.84 | FAAH (0.49) | FAAHALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL11557808 | 0.84 | TARBP2 (0.53) | ALDH1A1HPGDKDM4EMEN1NPC1 | |
| SCHEMBL6919654 | 0.83 | TARBP2 (0.54) | FAAHGAAMEN1NPC1RAB9A | |
| SCHEMBL15464213 | 0.81 | CA1 (0.50) | FAAHALDH1A1HSD17B10NPC1TP53 | |
| SCHEMBL6833976 | 0.81 | FAAH (0.52) | FAAHALDH1A1HPGDKDM4ENPC1 | |
| SCHEMBL1756314 | 0.80 | FAAH (0.53) | FAAHALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL15499845 | 0.80 | POLB (0.45) | FAAHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836073-B | 1- (5- (2-Cyanopyridin-4-yl) oxazole-2-carbonyl) -4-methylhexahydropyrrolo [3,4-B ] pyrrole-5 (1H) -carbonitrile as a USP30 inhibitor for the treatment of mitochondrial dysfunction, cancer and fibrosis | 特殊治疗有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | MISSION THERAPEUTICS LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | MISSION THERAPEUTICS LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| CN-115836073-A | 1- (5- (2-cyanopyridin-4-yl) oxazole-2-carbonyl) -4-methylhexahydropyrrolo [3,4-B ] pyrrole-5 (1H) -carbonitrile as a USP30 inhibitor for the treatment of mitochondrial dysfunction, cancer and fibrosis | 特殊治疗有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2021249909-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-16 | — | — | WO | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1831212-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1699801-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006065217-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005061510-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | CDC7 2176/4885DBF4 2329/4885FAAH 1139/4885 |
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | USP30, USP1, USP28 | CDC7 715/4885DBF4 969/4885FAAH 2684/4885 |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNB1, CHRNA2 | CDC7 3062/4885DBF4 3212/4885FAAH 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.